News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bioptigen Receives European Approval for Eye-Imaging Tool



12/19/2011 7:30:02 AM

Triangle Business Journal by Jason deBruyn, Staff Writer

Medical device company Bioptigen has received approval to market an eye-imaging tool in Europe.

Based in Research Triangle Park, Bioptigen focuses on devices to take detailed images of the eye. The company is a spinout from the Duke University Biomedical Engineering Department.

Sales projections were not publicly available. The company has raised about $7.5 million since 2005 through investors and grants. In a previous interview, Bioptigen President and CEO Eric Buckland said the private capital came primarily from angel investors.

“We are seeking to grow in the medical device space without the venture capital,” he said in November.

The approved device, the hand-held Envisu C2000-series, is intended for clinical use in the European Union.




comments powered by Disqus
Bioptigen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES